Merck/Moderna cancer vaccine cuts risk of death or recurrence from melanoma by over 40% - Reuters

The personalized cancer vaccine intismeran autogene, developed by Moderna and Merck, reduced the risk of melanoma recurrence or death by 42% when paired with Keytruda. Additionally, the combination decreased the risk of cancer spreading or death by 38% compared to using Keytruda alone. Despite these promising clinical outcomes, Moderna shares plunged up to 25% following a leak of partial data, a selloff analysts attribute to inflated investor expectations rather than the actual clinical results.